ΕΝΔΟΚΡΙΝΟΛΟΓΟΣ ΔΙΔΑΚΤΩΡ ΙΑΤΡΙΚΗΣ ΣΧΟΛΗΣ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ
Δρ ΘΩΜΑΣ ΠΑΤΕΡΑΚΗΣ MD, PhD
ΘΥΡΕΟΕΙΔΗΣ
ΟΣΤΑ
ΣΑΚΧΑΡΩΔΗΣ ΔΙΑΒΗΤΗΣ
ΜΕΤΑΒΟΛΙΣΜΟΣ
Νεώτερα από την Ενδοκρινολογία

 


Οι επισκέπτες μέσα από την ιστοσελίδα αυτή μπορούν να ενημερώνονται για τα νεώτερα κλινικά δεδομένα και τις εξελίξεις στην Ενδοκρινολογία που προκύπτουν και τους αφορούν. 

 


 

January 02, 2019

Thyroid Nodule Size Irrelevant When It Comes to Malignancy


Rates of malignancy and false-negative FNA results vary but, in most studies, are not higher in larger nodules. Patients with large, cytologically benign thyroid nodules need not undergo immediate surgical resection, as false-negative FNA rates are low and are expected to decrease in light of nomenclature revision of a subset of follicular variants of papillary thyroid carcinoma.

►Thyroid: Vol. 28, No. 12


 

January 08, 2019

Persistent Hot Flashes Increase Breast Cancer Risk in Women

 

Postmenopausal women who experience persistent hot flashes are more likely to be diagnosed with breast cancer than women who never experience vasomotor symptoms, but they are not more likely to die from it, a new long-term analysis from the Women's Health Initiative suggests.

Menopause: December 28, 2018 - Volume Publish Ahead of Print - Issue - p

 

January 09, 2019

Osteoporosis Drug Romosozumab Gains First Approval, in Japan

The osteoporosis drug romosozumab (Amgen/Astellas BioPharma) has been approved in its first market worldwide, in Japan, for the treatment of osteoporosis in women at high risk of fracture, where it will be known as Evenity, the companies have announced.